{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T19:59:38Z","timestamp":1765742378246},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,10,17]],"date-time":"2013-10-17T00:00:00Z","timestamp":1381968000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Chronic kidney disease\u2013mineral and bone disorder (CKD\u2013MBD) is a common complication in CKD patients, particularly in those with end-stage renal disease that requires dialysis. Lanthanum carbonate (LC) is a potent, non-aluminum, non-calcium phosphate binder. This systematic review evaluates the efficacy and safety of LC in CKD-MBD treatment for maintenance-dialysis patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A systematic review and meta-analysis on randomized controlled trials (RCTs) and quasi-RCTs was performed to assess the efficacy and safety of LC in maintenance hemodialysis or peritoneal dialysis patients. Analysis was performed using the statistical software Review Manager 5.1.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Sixteen RCTs involving 3789 patients were identified and retained for this review. No statistical difference was found in all-cause mortality. The limited number of trials was insufficient to show the superiority of LC over other treatments in lowering vascular calcification or cardiovascular events and in improving bone morphology, bone metabolism, or bone turn-over parameters. LC decreased the serum phosphorus level and calcium \u00d7 phosphate product (Ca \u00d7 P) as compared to placebo. LC, calcium carbonate (CC), and sevelamer hydrochloride (SH) were comparable in terms of controlling the serum phosphorus, Ca \u00d7 P product, and intact parathyroid hormone (iPTH) levels. However, LC resulted in a lower serum calcium level and a higher bone-specific alkaline phosphatase level compared with CC. LC had higher total cholesterol and low-density lipoprotein (LDL) cholesterol levels compared with SH. LC-treated patients appeared to have a higher rate of vomiting and lower risk of hypercalcemia, diarrhea, intradialytic hypotension, cramps or myalgia, and abdominal pain. Meta-analysis showed no significant difference in the incidence of other side effects. Accumulation of LC in blood and bone was below toxic levels.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>LC has high efficacy in lowering serum phosphorus and iPTH levels without increasing the serum calcium. Current evidence does not show a higher rate of adverse effects for LC compared with other treatments, except for a higher incidence of vomiting. Moreover, LC accumulation in blood and bone was below toxic levels. Well-designed studies should be conducted to evaluate the long-term effects of LC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2369-14-226","type":"journal-article","created":{"date-parts":[[2013,10,17]],"date-time":"2013-10-17T11:01:23Z","timestamp":1382007683000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Efficacy and safety of lanthanum carbonate on chronic kidney disease\u2013mineral and bone disorder in dialysis patients: a systematic review"],"prefix":"10.1186","volume":"14","author":[{"given":"Chenglong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junming","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,17]]},"reference":[{"key":"646_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Dr\u00fceke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, Kidney Disease: Improving Global Outcomes (KDIGO): Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006, 69: 1945-1953. 10.1038\/sj.ki.5000414.","journal-title":"Kidney Int"},{"issue":"1","key":"646_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/sj.ki.5002009","volume":"71","author":"A Levin","year":"2007","unstructured":"Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007, 71 (1): 31-38. 10.1038\/sj.ki.5002009.","journal-title":"Kidney Int"},{"key":"646_CR3","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/S0272-6386(00)70064-3","volume":"35","author":"GA Block","year":"2000","unstructured":"Block GA, Pork FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis. 2000, 35: 1226-1237. 10.1016\/S0272-6386(00)70064-3.","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"646_CR4","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1001\/jama.2011.308","volume":"305","author":"SC Palmer","year":"2011","unstructured":"Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF: Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011, 305 (11): 1119-1127. 10.1001\/jama.2011.308.","journal-title":"JAMA"},{"key":"646_CR5","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1053\/j.ajkd.2008.05.020","volume":"52","author":"R Wald","year":"2008","unstructured":"Wald R, Sarnak MJ, Tighiouart H, Cheung AK, Levey AS, Eknoyan G, Miskulin DC: Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study. Am J Kidney Dis. 2008, 52: 531-540. 10.1053\/j.ajkd.2008.05.020.","journal-title":"Am J Kidney Dis"},{"key":"646_CR6","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","volume":"52","author":"F Tentori","year":"2008","unstructured":"Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK: Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008, 52: 519-530. 10.1053\/j.ajkd.2008.03.020.","journal-title":"Am J Kidney Dis"},{"key":"646_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ndt\/gfg1002","volume":"18","author":"WG Goodman","year":"2003","unstructured":"Goodman WG: Medical management of secondary hyperparathyroidism in chronic renal failure. Nephrol Dial Transplant. 2003, 18: 2-8. 10.1093\/ndt\/gfg1032.","journal-title":"Nephrol Dial Transplant"},{"key":"646_CR8","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1038\/ki.1986.10","volume":"29","author":"B Ihle","year":"1986","unstructured":"Ihle B, Becker G, Kincaid-Smith P: Clinical and biochemical features of aluminium-related bone disease. Kidney Int. 1986, 29: S80-S86. 10.1038\/ki.1986.10.","journal-title":"Kidney Int"},{"issue":"5","key":"646_CR9","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1046\/j.1525-139X.2002.00077_1.x","volume":"15","author":"G Block","year":"2002","unstructured":"Block G, Uribarri J, Coladonato JA, Fan SL, Cunningham J, Nolan CR, Qunibi WY, Lindberg JS: How should hyperphosphatemia be managed in dialysis patients?. Semin Dial. 2002, 15 (5): 315-328. 10.1046\/j.1525-139X.2002.00077_1.x.","journal-title":"Semin Dial"},{"key":"646_CR10","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","volume":"342","author":"WG Goodman","year":"2000","unstructured":"Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000, 342: 1478-1483. 10.1056\/NEJM200005183422003.","journal-title":"N Engl J Med"},{"key":"646_CR11","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S0272-6386(99)70221-0","volume":"33","author":"AJ Bleyer","year":"1999","unstructured":"Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E: A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis. 1999, 33: 694-701. 10.1016\/S0272-6386(99)70221-0.","journal-title":"Am J Kidney Dis"},{"key":"646_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1523-1755.1999.00240.x","volume":"55","author":"EA Slatopolsky","year":"1999","unstructured":"Slatopolsky EA, Burke SK, Dillon MA: RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int. 1999, 55: 299-307. 10.1046\/j.1523-1755.1999.00240.x.","journal-title":"Kidney Int"},{"issue":"90","key":"646_CR13","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1111\/j.1523-1755.2004.09007.x","volume":"9","author":"B Brezina","year":"2004","unstructured":"Brezina B, Qunibi WY, Nolan CR: Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications. Kidney Int Suppl. 2004, 9 (90): S39-S45.","journal-title":"Kidney Int Suppl"},{"key":"646_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.5414\/CNP62104","volume":"62","author":"J Braun","year":"2004","unstructured":"Braun J, Asmus HG, Holzer H, Brunkhorst R, Krause R, Schulz W, Neumayer HH, Raggi P, Bommer J: Long-term comparison of a calcium-free phosphate binder and calcium carbonate \u2013 phosphorus metabolism and cardiovascular calcification. Clin Nephrol. 2004, 62: 104-115. 10.5414\/CNP62104.","journal-title":"Clin Nephrol"},{"key":"646_CR15","first-page":"688","volume":"6","author":"F Locatelli","year":"2003","unstructured":"Locatelli F, D\u2019Amico M, Pontoriero G: Lanthanum carbonate. Drugs. 2003, 6: 688-695.","journal-title":"Drugs"},{"key":"646_CR16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/01.mnh.0000133973.86816.e9","volume":"13","author":"GJ Behets","year":"2004","unstructured":"Behets GJ, Verberckmoes SC, D\u2019Haese PC, de Broe ME: Lanthanum carbonate: a new phosphate binder. Curr Opin Nephrol Hypertens. 2004, 13: 403-409. 10.1097\/01.mnh.0000133973.86816.e9.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"646_CR17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.5414\/CNP62193","volume":"62","author":"WF Finn","year":"2004","unstructured":"Finn WF, Joy MS, Hladik GA, And the Lanthanum Study Group: Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol. 2004, 62: 193-201. 10.5414\/CNP62193.","journal-title":"Clin Nephrol"},{"key":"646_CR18","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1093\/ndt\/gfh282","volume":"19","author":"AJ Hutchison","year":"2004","unstructured":"Hutchison AJ, Speake M, Al Baaj F: Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol Dial Transplant. 2004, 19: 1902-1906. 10.1093\/ndt\/gfh282.","journal-title":"Nephrol Dial Transplant"},{"key":"646_CR19","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1440-1797.2010.01412.x","volume":"16","author":"ND Toussaint","year":"2011","unstructured":"Toussaint ND, Lau KK, Polkinghorne KR, Kerr PG: Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial. Nephrology (Carlton). 2011, 16: 290-298. 10.1111\/j.1440-1797.2010.01412.x.","journal-title":"Nephrology (Carlton)"},{"issue":"85","key":"646_CR20","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1046\/j.1523-1755.63.s85.18.x","volume":"6","author":"PC Haese","year":"2003","unstructured":"Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, Coen G, Sulowicz W, Ferreira A, Torres A, Curic S, Popovic M, Dimkovic N, de Broe ME: A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl. 2003, 6 (85): S73-S78.","journal-title":"Kidney Int Suppl"},{"key":"646_CR21","first-page":"284","volume":"70","author":"HH Malluche","year":"2008","unstructured":"Malluche HH, Siami GA, Swanepoel C, Wang GH, Mawad H, Confer S, Smith M, Pratt RD, Monier-Faugere MC: SPD405-307 Lanthanum Carbonate Study Group: Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol. 2008, 70: 284-295.","journal-title":"Clin Nephrol"},{"key":"646_CR22","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1093\/ndt\/gfl146","volume":"21","author":"GB Spasovski","year":"2006","unstructured":"Spasovski GB, Sikole A, Gelev S, Masin-Spasovska J, Freemont T, Webster I, Gill M, Jones C, De Broe ME, D\u2019Haese PC: Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant. 2006, 21: 2217-2224. 10.1093\/ndt\/gfl146.","journal-title":"Nephrol Dial Transplant"},{"key":"646_CR23","doi-asserted-by":"publisher","first-page":"191","DOI":"10.5414\/CNP65191","volume":"65","author":"WF Finn","year":"2006","unstructured":"Finn WF, SPD 405\u2013307 Lanthanum Study Group: Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol. 2006, 65: 191-202. 10.5414\/CNP65191.","journal-title":"Clin Nephrol"},{"key":"646_CR24","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1185\/03007990903399398","volume":"25","author":"R Wilson","year":"2009","unstructured":"Wilson R, Zhang P, Smyth M, Pratt R: Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. Current Medical Research & Opinion. 2009, 25: 3021-3028. 10.1185\/03007990903399398.","journal-title":"Current Medical Research & Opinion"},{"key":"646_CR25","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1053\/j.ajkd.2009.06.004","volume":"54","author":"SD Navaneethan","year":"2009","unstructured":"Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF: Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis. 2009, 54: 619-637. 10.1053\/j.ajkd.2009.06.004.","journal-title":"Am J Kidney Dis"},{"key":"646_CR26","volume-title":"The Cochrane Collaboration","author":"JPT Higgins","year":"2008","unstructured":"Higgins JPT, Green S: Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration. 2008, Editors Available from http:\/\/www.cochrane-handbook.org"},{"key":"646_CR27","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/sj.ki.5001932","volume":"71","author":"P Altmann","year":"2007","unstructured":"Altmann P, Barnett ME, Finn WF: Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Kidney Int. 2007, 71: 252-259. 10.1038\/sj.ki.5001932.","journal-title":"Kidney Int"},{"key":"646_CR28","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.2215\/CJN.04741107","volume":"3","author":"R Mehrotra","year":"2008","unstructured":"Mehrotra R, Martin KJ, Fishbane S, Sprague SM, Zeig S, Anger M, Fosrenol Overview Research Evaluation Study for Early Experience Study Group: Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. J Am Soc Nephrol. 2008, 3: 1437-1445. 10.2215\/CJN.04741107.","journal-title":"J Am Soc Nephrol"},{"key":"646_CR29","doi-asserted-by":"publisher","first-page":"216","DOI":"10.5414\/CN107257","volume":"78","author":"T Toida","year":"2012","unstructured":"Toida T, Fukudome K, Fujimoto S, Yamada K, Sato Y, Chiyotanda S, Kitamura K: Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study. Clin Nephrol. 2012, 78: 216-223. 10.5414\/CN107257.","journal-title":"Clin Nephrol"},{"key":"646_CR30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000088932","volume":"102","author":"J Alastair Hutchison","year":"2006","unstructured":"Alastair Hutchison J, Bart M, Johan V, Gernot A, Elfatih M, Roland S, Wolfgang B, Rene J, Andre V: Long-Term Efficacy and Tolerability of Lanthanum Carbonate: Results from a 3-Year Study. Nephron Clin Pract. 2006, 102: 61-71. 10.1159\/000088932.","journal-title":"Nephron Clin Pract"},{"key":"646_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000084653","volume":"100","author":"AJ Hutchison","year":"2005","unstructured":"Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, Backs W, Jamar R, Vosskuhler A: Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract. 2005, 100: 8-19. 10.1159\/000084653.","journal-title":"Nephron Clin Pract"},{"key":"646_CR32","doi-asserted-by":"publisher","first-page":"252","DOI":"10.5414\/CNP72252","volume":"72","author":"SM Sprague","year":"2009","unstructured":"Sprague SM, Ross EA, Nath SD, Zhang P, Pratt RD, Krause R: Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol. 2009, 72: 252-258. 10.5414\/CNP72252.","journal-title":"Clin Nephrol"},{"key":"646_CR33","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1744-9987.2012.01071.x","volume":"16","author":"S Kasai","year":"2012","unstructured":"Kasai S, Sato K, Murata Y, Kinoshita Y: Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis. Ther Apher Dial. 2012, 16: 341-349. 10.1111\/j.1744-9987.2012.01071.x.","journal-title":"Ther Apher Dial"},{"key":"646_CR34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1744-9987.2007.00541.x","volume":"12","author":"T Shigematsu","year":"2007","unstructured":"Shigematsu T, and the Lanthanum Carbonate Research Group: Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis. Ther Apher Dial. 2007, 12: 55-61.","journal-title":"Ther Apher Dial"},{"key":"646_CR35","doi-asserted-by":"publisher","first-page":"404","DOI":"10.5414\/CNP70404","volume":"70","author":"T Shigematsu","year":"2008","unstructured":"Shigematsu T, And the Lanthanum Carbonate Group: Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clin Nephrol. 2008, 70: 404-410. 10.5414\/CNP70404.","journal-title":"Clin Nephrol"},{"key":"646_CR36","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/ndt\/gfh693","volume":"20","author":"F Al-Baaj","year":"2005","unstructured":"Al-Baaj F, Speake M, Hutchison AJ: Control of serum phosphate by oral lanthanum carbonate in patients undergoing hemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study. Nephrol Dial Transplant. 2005, 20: 775-782. 10.1093\/ndt\/gfh693.","journal-title":"Nephrol Dial Transplant"},{"key":"646_CR37","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0272-6386(03)00554-7","volume":"42","author":"MS Joy","year":"2003","unstructured":"Joy MS, Finn WF: Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis. 2003, 42: 96-107. 10.1016\/S0272-6386(03)00554-7.","journal-title":"Am J Kidney Dis"},{"key":"646_CR38","doi-asserted-by":"publisher","first-page":"461","DOI":"10.5414\/CNP63461","volume":"63","author":"SS Chiang","year":"2005","unstructured":"Chiang SS, Chen JB, Yang WC: Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. Clin Nephrol. 2005, 63: 461-470. 10.5414\/CNP63461.","journal-title":"Clin Nephrol"},{"issue":"2","key":"646_CR39","doi-asserted-by":"publisher","first-page":"136","DOI":"10.5414\/CN107362","volume":"79","author":"YK Lee","year":"2013","unstructured":"Lee YK, Choi HY, Shin SK, Lee HY: Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study. Clin Nephrol. 2013, 79 (2): 136-142. 10.5414\/CN107362.","journal-title":"Clin Nephrol"},{"key":"646_CR40","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1471-2369-14-29","volume":"14","author":"X Jing","year":"2013","unstructured":"Jing X, Yi-Xiang Z, Xue-Qing Y, Zhi-Hong L, Li-Ning W, Jiang-Hua C, Ya-Ping F, Zhao-Hui N, Mei W, Fa-Huan Y, Guo-Hua D, Xiang-Mei C, Ai-Ping Z, Chang-Lin M: Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China. BMC Nephrol. 2013, 14: 29-10.1186\/1471-2369-14-29.","journal-title":"BMC Nephrol"},{"issue":"9","key":"646_CR41","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","volume":"72","author":"W Suki","year":"2007","unstructured":"Suki W, Zabaneh R, Cngiano J, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK: Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007, 72 (9): 1130-1137. 10.1038\/sj.ki.5002466.","journal-title":"Kidney Int"},{"issue":"86","key":"646_CR42","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1046\/j.1523-1755.63.s85.28.x","volume":"6","author":"M Salgueira","year":"2003","unstructured":"Salgueira M, del Toro N, Moreno-Alba R, Jim\u00e9nez E, Arest\u00e9 N, Palma A: Vascular calcification in the uremic patient: a cardiovascular risk?. Kidney Int Suppl. 2003, 6 (86): S119-S121.","journal-title":"Kidney Int Suppl"},{"issue":"2","key":"646_CR43","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/ndt\/gfr254","volume":"27","author":"IG Nikolov","year":"2012","unstructured":"Nikolov IG, Joki N, Nguyen-Khoa T, Guerrera IC, Maizel J, Benchitrit J, Machado Dos Reis L, Edelman A, Lacour B, Jorgetti V, Dr\u00fceke TB, Massy ZA: Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice. Nephrol Dial Transplant. 2012, 27 (2): 505-513. 10.1093\/ndt\/gfr254.","journal-title":"Nephrol Dial Transplant"},{"key":"646_CR44","doi-asserted-by":"publisher","first-page":"164A","DOI":"10.1681\/ASN.2007020156","volume":"19","author":"M Rodriguez","year":"2008","unstructured":"Rodriguez M, Guerrero F, Lopez I, Aguilera-Tejero E, Rodriguez M: Lanthanum carbonate and sevelamer hydrochloride prevent vascular calcification in uremic rats. J Am Soc Nephrol. 2008, 19: 164A-10.1681\/ASN.2007020156.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"646_CR45","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1046\/j.1523-1755.2002.00459.x","volume":"62","author":"W Braunlin","year":"2002","unstructured":"Braunlin W, Zhorov E, Guo A, Apruzzese W, Xu Q, Hook P, Smisek DL, Mandeville WH, Holmes-Farley SR: Bile acid binding to sevelamer HCl. Kidney Int. 2002, 62 (2): 611-619. 10.1046\/j.1523-1755.2002.00459.x.","journal-title":"Kidney Int"},{"issue":"5","key":"646_CR46","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1159\/000135691","volume":"28","author":"MC Perianayagam","year":"2008","unstructured":"Perianayagam MC, Jaber BL: Endotoxin-binding affinity of sevelamer hydrochloride. Am J Nephrol. 2008, 28 (5): 802-807. 10.1159\/000135691.","journal-title":"Am J Nephrol"},{"issue":"3","key":"646_CR47","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000319850","volume":"30","author":"AB Hauser","year":"2010","unstructured":"Hauser AB, Azevedo IR, Gon\u00e7alves S, Stinghen A, Aita C, Pecoits-Filho R: Sevelamer carbonate reduces inflammation and endotoxemia in an animal model of uremia. Blood Purif. 2010, 30 (3): 153-158. 10.1159\/000319850.","journal-title":"Blood Purif"},{"issue":"4","key":"646_CR48","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1159\/000302723","volume":"29","author":"AE Stinghen","year":"2010","unstructured":"Stinghen AE, Gon\u00e7alves SM, Bucharles S, Branco FS, Gruber B, Hauser AB, Pecoits-Filho R: Sevelamer decreases systemic inflammation in parallel to a reduction in endotoxemia. Blood Purif. 2010, 29 (4): 352-356. 10.1159\/000302723.","journal-title":"Blood Purif"},{"issue":"9","key":"646_CR49","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.2215\/CJN.01650211","volume":"6","author":"JF Navarro-Gonz\u00e1lez","year":"2011","unstructured":"Navarro-Gonz\u00e1lez JF, Mora-Fern\u00e1ndez C, Muros De Fuentes M, Donate-Correa J, Caza\u00f1a-P\u00e9rez V, Garc\u00eda-P\u00e9rez J: Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. Clin J Am Soc Nephrol. 2011, 6 (9): 2272-2279. 10.2215\/CJN.01650211.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"646_CR50","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1755-6686.2013.12009.x","volume":"39","author":"SP Chennasamudram","year":"2013","unstructured":"Chennasamudram SP, Noor T, Vasylyeva TL: Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis. J Ren Care. 2013, 39 (2): 82-89. 10.1111\/j.1755-6686.2013.12009.x.","journal-title":"J Ren Care"},{"issue":"6","key":"646_CR51","doi-asserted-by":"publisher","first-page":"934","DOI":"10.2215\/CJN.12891211","volume":"7","author":"H Vlassara","year":"2012","unstructured":"Vlassara H, Uribarri J, Cai W, Goodman S, Pyzik R, Post J, Grosjean F, Woodward M, Striker GE: Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol. 2012, 7 (6): 934-942. 10.2215\/CJN.12891211.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"646_CR52","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/S0735-1097(02)01937-X","volume":"40","author":"W Koenig","year":"2002","unstructured":"Koenig W, Khuseyinova N, Hoffmann MM, M\u00e4rz W, Fr\u00f6hlich M, Hoffmeister A, Brenner H, Rothenbacher D: D14 C(\u2212260) T polymorphism, plasma levels of the soluble endotoxin receptor CD14, their association with chronic infections and risk of stable coronary artery disease. J Am Coll Cardiol. 2002, 40 (1): 34-42. 10.1016\/S0735-1097(02)01937-X.","journal-title":"J Am Coll Cardiol"},{"key":"646_CR53","doi-asserted-by":"publisher","first-page":"386","DOI":"10.5414\/CNP68386","volume":"68","author":"J Delmez","year":"2007","unstructured":"Delmez J, Block G, Robertson J, Chasan-Taber S, Blair A, Dillon M, Bleyer AJ: A randomized, doubleblind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol. 2007, 68: 386-391. 10.5414\/CNP68386.","journal-title":"Clin Nephrol"},{"issue":"1","key":"646_CR54","doi-asserted-by":"publisher","first-page":"c15","DOI":"10.1159\/000149239","volume":"110","author":"AJ Hutchison","year":"2008","unstructured":"Hutchison AJ, Barnett ME, Krause R, Kwan JT, Siami GA, SPD405-309 Lanthanum Study Group: Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract. 2008, 110 (1): c15-c23. 10.1159\/000149239.","journal-title":"Nephron Clin Pract"},{"issue":"6","key":"646_CR55","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1111\/j.1523-1755.2005.00753.x","volume":"68","author":"E Slatopolsky","year":"2005","unstructured":"Slatopolsky E, Liapis H, Finch J: Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int. 2005, 68 (6): 2809-2813. 10.1111\/j.1523-1755.2005.00753.x.","journal-title":"Kidney Int"},{"issue":"3","key":"646_CR56","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/j.1523-1755.2005.00171.x","volume":"67","author":"B Lacour","year":"2005","unstructured":"Lacour B, Lucas A, Auchere D, Ruellan N, Serre Patey NM, Drueke TB: Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int. 2005, 67 (3): 1062-1069. 10.1111\/j.1523-1755.2005.00171.x.","journal-title":"Kidney Int"},{"issue":"Pt 2","key":"646_CR57","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1365-2818.2006.01601.x","volume":"223","author":"Z Yang","year":"2006","unstructured":"Yang Z, Schryvers D, Roels F, D\u2019Haese PC, De Broe ME: Demonstration of lanthanum in liver cells by energy-dispersive X-ray spectroscopy, electron energy loss spectroscopy and high-resolution transmission electron microscopy. J Microsc. 2006, 223 (Pt 2): 133-139.","journal-title":"J Microsc"},{"issue":"3","key":"646_CR58","doi-asserted-by":"publisher","first-page":"9321","DOI":"10.1186\/1752-1947-3-9321","volume":"9","author":"G Namagondlu","year":"2009","unstructured":"Namagondlu G, Main N, Yates L, Mooney J, Sathyamurthy S, Daryanani I, Crowe A, Ledson T, Banerjee A: Lanthanum associated abnormal liver function tests in two patients on dialysis: a case report. J Med Case Rep. 2009, 9 (3): 9321-","journal-title":"J Med Case Rep"},{"issue":"3","key":"646_CR59","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1523-1755.2004.00877.x","volume":"66","author":"B Manns","year":"2004","unstructured":"Manns B, Stevens L, Miskulin D, Owen WF, Winkelmayer WC, Tonelli M: A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int. 2004, 66 (3): 1239-1247. 10.1111\/j.1523-1755.2004.00877.x.","journal-title":"Kidney Int"},{"issue":"2","key":"646_CR60","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1053\/jarr.2003.50016","volume":"10","author":"SK Burke","year":"2003","unstructured":"Burke SK, Dillon MA, Hemken DE, Rezabek MS, Balwit JM: Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients. Adv Ren Replace Ther. 2003, 10 (2): 133-145. 10.1053\/jarr.2003.50016.","journal-title":"Adv Ren Replace Ther"},{"issue":"1","key":"646_CR61","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1524-4733.2006.00142.x","volume":"10","author":"A Brennan","year":"2007","unstructured":"Brennan A, Akehurst R, Davis S, Sakai H, Abbott V: The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease. Value Health. 2007, 10 (1): 32-41. 10.1111\/j.1524-4733.2006.00142.x.","journal-title":"Value Health"},{"issue":"4","key":"646_CR62","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1159\/000331988","volume":"58","author":"S Brunner-Ziegler","year":"2011","unstructured":"Brunner-Ziegler S, Fr\u00f6schl B, Hiebinger C, Zsifkovits J: Effectiveness and cost-efficacy of phosphate binders in hemodialysis. Ann Nutr Metab. 2011, 58 (4): 315-319. 10.1159\/000331988.","journal-title":"Ann Nutr Metab"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-14-226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2369-14-226\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-14-226","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-14-226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T01:45:16Z","timestamp":1630547116000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/1471-2369-14-226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,17]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["646"],"URL":"https:\/\/doi.org\/10.1186\/1471-2369-14-226","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,17]]},"assertion":[{"value":"23 April 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"226"}}